457 related articles for article (PubMed ID: 27891632)
1. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
2. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Mizokami Y; Oda K; Funao N; Nishimura A; Soen S; Kawai T; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1042-1051. PubMed ID: 28988197
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
4. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
6. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Hou X; Meng F; Wang J; Sha W; Chiu CT; Chung WC; Gu L; Kudou K; Chong CF; Zhang S
J Gastroenterol Hepatol; 2022 Jul; 37(7):1275-1283. PubMed ID: 35342997
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
Hirai A; Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Tominaga K; Tokioka S; Higuchi K
Dig Dis Sci; 2018 Apr; 63(4):974-981. PubMed ID: 29464587
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
Hamada K; Uedo N; Tonai Y; Arao M; Suzuki S; Iwatsubo T; Kato M; Shichijo S; Yamasaki Y; Matsuura N; Nakahira H; Kanesaka T; Yamamoto S; Akasaka T; Hanaoka N; Takeuchi Y; Higashino K; Ishihara R; Okada H; Iishi H; Fukui K; Shimokawa T
J Gastroenterol; 2019 Feb; 54(2):122-130. PubMed ID: 29943163
[TBL] [Abstract][Full Text] [Related]
12. Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor.
Kaneko E; Hoshihara Y; Sakaki N; Harasawa S; Ashida K; Asaka M; Asaki S; Nakamura T; Kobayashi K; Kajiyama G; Ogawa N; Yao T; Muto Y; Nakazawa S; Takemoto T
J Gastroenterol; 2000; 35(11):824-31. PubMed ID: 11085491
[TBL] [Abstract][Full Text] [Related]
13. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK; Choi MG; Choi SC; Lee KM; Kim TO; Park SH; Moon JS; Lim YJ; Kang DH; Cheon GJ; Baik GH; Kim KO; Cho KB; Jang JS; Park JJ; Son BK; Jung HK; Kim BW; Kim SK; Lee ST; Cha JM; Kim AR; Kim EJ; Park HW; Song GS
Aliment Pharmacol Ther; 2020 Sep; 52(5):789-797. PubMed ID: 32701188
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
Tan ND; Liu XW; Liu CX; Li SB; Chen HH; Li X; Wu H; Liao AJ; Zhen YB; Shen PZ; Huo LJ; Liu HL; Shi RH; Zhang BQ; Zhang ZY; Wang JN; Zhan Q; Deng H; Shu X; Tuo BG; Wang QZ; Du SY; Qi LZ; Zhang GX; Peng Q; Wang BM; Ye B; Chen MH; Xiao YL
J Gastroenterol Hepatol; 2022 Nov; 37(11):2060-2066. PubMed ID: 36068945
[TBL] [Abstract][Full Text] [Related]
19. Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Fujino MA; Morozumi A; Kobayashi K; Ueda F; Suzuki Y; Uchida N; Tachikawa H; Sano S; Ohtsuka H; Yamamoto Y
J Clin Gastroenterol; 1995; 20 Suppl 2():S44-6. PubMed ID: 7594338
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
Kawai D; Takenaka R; Ishiguro M; Okanoue S; Gotoda T; Kono Y; Takemoto K; Tsugeno H; Fujiki S
BMC Gastroenterol; 2021 May; 21(1):236. PubMed ID: 34022796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
